Overview
This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.
Eligibility
Inclusion Criteria:
- Currently pregnant
- Two-parent families or single-parent families
- Current or new patient at Weissbluth Pediatrics
Exclusion Criteria:
- Adopting parents
- Multiple pregnancy (twins, triplets, etc.)
- Siblings (one enrolled child per family)


